Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Allogene Therapeutics to post earnings of ($0.34) per share and revenue of $0.01 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Allogene Therapeutics Price Performance

Shares of Allogene Therapeutics stock traded up $0.16 during trading on Friday, reaching $2.18. 4,700,933 shares of the company traded hands, compared to its average volume of 3,084,437. Allogene Therapeutics has a 1-year low of $1.32 and a 1-year high of $5.42. The company has a 50 day moving average price of $1.96 and a 200-day moving average price of $2.34. The firm has a market capitalization of $457.08 million, a PE ratio of -1.40 and a beta of 1.02.

Analyst Ratings Changes

Several research analysts have weighed in on ALLO shares. Piper Sandler lowered their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. William Blair restated an "outperform" rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $9.95.

Remove Ads

Insider Transactions at Allogene Therapeutics

In other news, EVP Zachary Roberts sold 27,199 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. This represents a 5.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now owns 250,713 shares of the company's stock, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,846 shares of company stock worth $112,042 in the last quarter. 24.30% of the stock is currently owned by corporate insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).